Clinical relevance of non-tuberculous mycobacteria isolated from respiratory specimens: seven year experience in a UK hospital

Schiff, H F; Jones, Sasia; Achaiah, Andrew; Pereira, Ana Margarida; Stait, G; Green, B

doi:10.1038/s41598-018-37350-8

Cited by 36 publications

(31 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…N ontuberculous mycobacteria (NTM) are comprised of >150 species (1) and are increasingly recognized as opportunistic pathogens (2). In addition, frequency of disease-causing NTM isolation has been rising in many settings (3,4). The exact epidemiology of NTM pulmonary disease, the most common manifestation in adults (3), has been difficult to determine because reporting is not mandatory in most countries and identification of true disease is often difficult (5).…”

mentioning

confidence: 99%

Species Distribution and Isolation Frequency of Nontuberculous Mycobacteria, Uruguay

Greif¹,

Coitinho²,

Ingen³

et al. 2020

Emerg. Infect. Dis.

View full text Add to dashboard Cite

mentioning

confidence: 99%

Species Distribution and Isolation Frequency of Nontuberculous Mycobacteria, Uruguay

Greif¹,

Coitinho²,

Ingen³

et al. 2020

Emerg. Infect. Dis.

View full text Add to dashboard Cite

“…Possible differential diagnoses for a thin-walled cavitary pulmonary lesion in HIV-seropositive cases include tuberculosis, invasive aspergillosis, Pneumocystis jirovecii pneumonia, endemic fungal infections, rheumatoid arthritis, as well as nontuberculous mycobacterium. CT images show a cavitary lesion in 46%, nodules in 29%, and the tree-in-bud sign in 21% of cases of NTM-PD [4]. In our case, a thin built middle age lady has tree-in-bud in lingula and cavitary lesion in the right middle lobe on CT imaging.…”

Section: Discussionmentioning

confidence: 52%

Nontuberculous Mycobacterial Pulmonary Disease in an Immunocompromised Patient

Singh¹,

Kumar²

2019

Cureus

View full text Add to dashboard Cite

In this article, we discuss the nontuberculous mycobacterial pulmonary disease in a 40-yearold HIV-seropositive female patient. The patient has a history of pulmonary tuberculosis, experienced two years ago. At the time, she was treated successfully with anti-tuberculous therapy. A chest x-ray (CXR) and computed tomography (CT) scan of the chest showed a thinwalled cavitary lesion in the right lung. In addition, the tree-in-bud sign, indicative of airway obstruction, was present on CT imaging. Fluorescence microscopy using auramine staining showed acid-fast bacilli (AFB) in sputum smears on more than two samples. Mycobacterium tuberculosis was not detected in the nucleic acid amplification test in the same sample. The AFB identified were mycobacteria other than tubercle bacilli, i.e., nontuberculous mycobacteria, that cause cavitary lung disease. Culture in liquid media and subsequent molecular analysis showed Mycobacterium avium complex (MAC). The patient is now being treated with a multidrug regimen of antibiotics and has improved, with documented sputum conversion.

show abstract

“…7 8 Mycobacterium avium complex (MAC, including M. avium, M. intracellulare and M. chimaera), and M. abscessus are associated with around 90% of the total number of reported cases of NTM-PD. [9][10][11] Uncertainties around the management of NTM-PD include its epidemiology, diagnosis, treatment and prevention. These are addressed to some extent in the 2017 British Thoracic Society (BTS) guidelines 12 ; however, variations in care remain for UK patients with NTM-PD.…”

Section: Introductionmentioning

confidence: 99%

Current and future management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in the UK

et al. 2020

View full text Add to dashboard Cite

A rising number of non-tuberculous mycobacterial (NTM) isolates are being identified in UK clinical practice. There are many uncertainties around the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD), including its epidemiology, diagnosis, treatment and prevention. Regional variations in how patients with NTM-PD are managed reflects the lack of standardised pathways in the UK. Service optimisation and multidisciplinary working can improve the quality of care for patients with NTM-PD, including (1) better identification of patients at risk of NTM-PD and modification of risk factors where applicable; (2) standardisation of reference laboratory testing to offer clinicians access to accurate and prompt information on NTM species and drug sensitivities; (3) development of recognised specialist NTM nursing care; (4) standardisation of NTM-PD imaging strategies for monitoring of treatment and disease progression; (5) establishment of a hub-and-spoke model of care, including clear referral and management pathways, dedicated NTM-PD multidisciplinary teams, and long-term patient follow-up; (6) formation of clinical networks to link experts who manage diseases associated with NTM; (7) enabling patients to access relevant support groups that can provide information and support for their condition; and (8) development of NTM research groups to allow patient participation in clinical trials and to facilitate professional education.

show abstract

Clinical relevance of non-tuberculous mycobacteria isolated from respiratory specimens: seven year experience in a UK hospital

Cited by 36 publications

References 19 publications

Species Distribution and Isolation Frequency of Nontuberculous Mycobacteria, Uruguay

Species Distribution and Isolation Frequency of Nontuberculous Mycobacteria, Uruguay

Nontuberculous Mycobacterial Pulmonary Disease in an Immunocompromised Patient

Current and future management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in the UK

Contact Info

Product

Resources

About